Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Use of Signal Transduction Inhibitors to Treat Cancer in Children Questioned

By Biotechdaily staff writers
Posted on 24 Mar 2008
A drug that had been found effective for treating medulloblastoma, a type of brain tumor found mostly in children, in a mouse model has now been found to cause permanent bone damage in young mice and may not be appropriate for use in human children.

In 2004 researchers treated mice from a line that had been genetically engineered to develop medulloblastoma with oral doses of HhAntag, a signal transduction inhibitor (STI) known to block the function of a molecule called smoothened (Smo). More...
The suppression of Smo also suppressed several genes that are critical to triggering and driving tumor growth. The compound inhibited cell proliferation and led to the death of tumor cells, resulting in regression of the medulloblastoma. The Smo protein is part of a biochemical cascade of reactions called the Sonic Hedgehog pathway (Shh). The Shh pathway triggers normal growth of the cerebellum in the fetus, but abnormal activity during infancy and early childhood causes medulloblastoma. The hedgehog pathway does not function in tumor cells cultured in dishes: only animal studies were able to show that HhAntag could halt and reverse an otherwise fatal cancer.

In the current study, investigators at The Children's Hospital of Philadelphia (PA, USA) tested HhAntag on young mice, 10 to 14 days old, in contrast to the adult mice tested previously. They reported in the March 2008 issue of the journal Cancer Cell that when examined after only four doses of the drug, the treated mice were found to be smaller with lower weight and shorter bones than untreated mice, and the effects were not reversible.

"We already knew that the same biological pathway involved in the growth of tumors was also involved in bone development,” said senior author Dr. Tom Curran, professor of developmental biology at The Children's Hospital of Philadelphia, "but we did not expect temporary inhibition to cause an irreversible change in bone growth. While it is not clear that the bone defects we observed in mice would also occur in children, and while signal transduction inhibitors may still represent a highly promising approach to treating pediatric cancer, it may be important to perform pre-clinical testing in young animals before moving ahead to clinical trials. Signal transduction inhibitors such as this drug may still prove beneficial in treating children's cancers, but our findings raise questions about possible adverse effects during childhood development.”


Related Links:
The Children's Hospital of Philadelphia

Gold Member
Hematology Analyzer
Medonic M32B
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Homocysteine Quality Control
Liquichek Homocysteine Control
Pipette
Accumax Smart Series
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.